RE:CD8+ TiLs and T-cell exhaustionRelated to the activation of T-cells within the TME is the Phase 1 company Janus Therapeutics which is developing a bispecific and is currently trading at approximately US$50 and a market cap of US$2.5 Billiion.
"Janux’s initial development programs are designed to activate T cells within the tumor microenvironment. The company leverages its proprietary tumor activated T cell engager (TRACTr) and its tumor activated immunomodulator (TRACIr) platforms to develop bispecific molecules that once activated are precision engineered to bind to specific tumor antigens and to T cells, thereby focusing T cells to attack the cancer while limiting toxicity elsewhere in the body. Activation of the TRACTrs and TRACIrs within the tumor microenvironment limits toxicity elsewhere in the body."
https://www.januxrx.com/developement-pipeline/